Using of SGLt2 Inhibitors in Patients With Type 2 DM

Not yet recruitingOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 30, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

SGLT2 inhibitor

a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.

All Listed Sponsors

lead

Assiut University

OTHER

NCT06268977 - Using of SGLt2 Inhibitors in Patients With Type 2 DM | Biotech Hunter | Biotech Hunter